About Courtagen
Courtagen was a Healthcare company based in Woburn (United States) founded in 2009 by Brian McKernan. It provides solutions for neurological and metabolic disorders. It operates on a B2B model. Courtagen has raised $41.31 million across 6 funding rounds from investors including Adler & Co, Bunker Hill Capital and First Analysis. The company has 128 employees. Courtagen has completed 1 acquisition, including Medicinal Genomics. Its chief executive, as recorded, is Brian McKernan. The company is recorded as dissolved. Its focus areas include Biotechnology, Neurological and Metabolic Disorders and Therapeutic Solutions. Its legal entity is COURTAGEN LIFE SCIENCES, INC. Its competitors include BrainSpec, Neurovigil and Quadrant Biosciences; 2 of its 3 listed competitors have raised funding.
Company details
Courtagen, founded in 2009 in Woburn, United States, focuses on providing healthcare solutions, advancing biotech innovations, neurological and metabolic disorders, and therapeutic solutions. Provides solutions for neurological and metabolic disorders. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters Woburn, United States
- Employees 128
- Founders Brian McKernan
- SectorsHealthcare
- Website courtagen.com
- Social X
- Legal Name Courtagen Life Sciences, Inc.
- Total Equity Funding$41.31M (USD)
in 6 rounds
- Latest Funding Round$20M (USD), Series C
Jun 2015
- InvestorsAdler & Co.
& 3 more
- Employee Count128
- Investments & Acquisitions
Funding Insights of Courtagen
Courtagen has successfully raised a total of $41.31M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $41.31M
- Total Rounds 6
- Last Round Series C — $20M
- Investors Count 4
All 6 funding rounds of Courtagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $20M | Series C | – | Adler & Co, Bunker Hill Capital | – |
| Jun 2014 | $6.3M | Series B | – | – | – |
| Oct 2011 | $8M | Series B | – | – | – |
| Jun 2011 | Series A | – | – | – | |
| Jul 2010 | $7.01M | Series A | – | – | – |
| Jun 2010 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Courtagen
Courtagen has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Adler & Co, Bunker Hill Capital and First Analysis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term growth capital is invested in lower middle market companies. | bunkerhillcapital.com | Wellesley Hills, United States | ||
Venture capital and transaction advisory services for B2B tech companies. | firstanalysis.com | |||
Tech & Life Science focused early stage VC firm investing in the US | hlcp.com | Keene, United States | ||
Adler & Co. is engaged in matching business owners with buyers. | adlercompany.com | Boulder, United States |
Investor details for Courtagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Courtagen
1 people are tracked at Courtagen (1 in leadership); the tracked headcount is 128.
| Name | Role | Group |
|---|---|---|
Brian McKernan | Co-Founder, CEO | Leadership |
Complete people profiles for Courtagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Courtagen
Courtagen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Medicinal Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of cannabis sequencing services | medicinalgenomics.com | Woburn, United States | 2011 | Jan 2012 | •••• |
Complete acquisition details for Courtagen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Courtagen
4 dated milestones of Courtagen across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Courtagen is founded.
- Funding First funding round.
- Acquisition Acquires Medicinal Genomics.
- Funding Latest funding round, Series C, of $20.0M.
Competitors of Courtagen
Courtagen has 3 listed competitors in our database, 2 of them funded. They include BrainSpec, Neurovigil and Quadrant Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| brainspecmed.com | 2015 | Boston, United States | $5.59M | Web-based MRS platform for brain metabolite analysis is utilized. | ||
| neurovigil.com | 2007 | Mountain View, United States | $250,000 | Solution provider for analysis of brain data in medical applications | ||
| quadrantbiosciences.com | 2015 | Syracuse, United States | Technologies for the evaluation of brain health and autism spectrum disorders |
Detailed competitors of Courtagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Courtagen (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Courtagen
Courtagen was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Courtagen is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.
Brian McKernan is the CEO of Courtagen, as recorded in our data. They have also founded this company.
Courtagen is a funded company, having raised a total of $41.31M across 6 funding rounds to date.
Courtagen has 128 employees.
Courtagen, founded in 2009 in Woburn, United States, focuses on providing healthcare solutions, advancing biotech innovations, neurological and metabolic disorders, and therapeutic solutions. Provides solutions for neurological and metabolic disorders. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Courtagen's top competitors include BrainSpec, Quadrant Biosciences and Neurovigil.
Courtagen has made 1 acquisition, including Medicinal Genomics.
Courtagen has 4 investors. Key investors include Adler & Co, Bunker Hill Capital, First Analysis, and Harbor Light Capital Partners.
Courtagen operates through Courtagen Life Sciences, Inc..